Hepatitis C
FDA Approves HCV Rapid Antibody Test for Fingerstick Blood Samples
- Details
- Category: HCV Testing & Diagnosis
- Published on Friday, 25 February 2011 02:06
Anadys Starts Phase 2b Study of HCV Polymerase Inhibitor ANA598
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 01 February 2011 12:41
Anadys Pharmaceuticals announced this week that it has begun treating the first participants in a Phase 2b clinical trial of its investigational hepatitis C virus (HCV) polymerase inhibitor ANA598. The new drug will be tested in combination with pegylated interferon plus ribavirin in both previously untreated patients and people who did not achieve sustained response to prior therapy.
Anemia during Hepatitis C Treatment Predicts Sustained Response to Pegylated Interferon/ribavirin
- Details
- Category: Side Effects - HCV
- Published on Monday, 10 January 2011 16:00
Hepatitis C patients who develop anemia during treatment with pegylated interferon plus ribavirin are more likely to achieve a sustained virological response (SVR), according to data from the IDEAL trial published in the November 2010 issue of Gastroenterology. Both ribavirin dose reduction -- which did not decrease SVR -- and medications that stimulate red blood cell production may be used to manage anemia and help people stay on treatment, the study authors concluded.
10 Million Injection Drug Users May Have Hepatitis B or C
- Details
- Category: Hepatitis B
- Published on Saturday, 29 January 2011 00:00
Approximately 10 million injection drug users (IDUs) worldwide might be infected with hepatitis C virus (HCV), and more than 1 million may be living with hepatitis B, according to a meta-analysis of data from over 70 countries published in the July 28, 2011, advance online edition of The Lancet. 
Drinking More Coffee Linked to Improved Response to Hepatitis C Treatment
- Details
- Category: HCV Treatment
- Published on Friday, 03 December 2010 12:48
Previous research has shown that drinking more coffee is associated with better liver health and slower liver disease progress, but its relationship to hepatitis C virus (HCV) treatment response is not fully understood.
World Hepatitis Day Gets Global Recognition
- Details
- Category: Hepatitis B
- Published on Saturday, 29 January 2011 00:00
July 28 was recognized as World Hepatitis Day, garnering attention from news media worldwide.
The date was chosen to honor Dr. Baruch Blumberg, who discovered the hepatitis B virus (HBV) in 1967 and later developed an effective vaccine and won the Nobel Prize.
Danish Study Looks at Hepatitis C Sexual Transmission among HIV Positive Gay Men
- Details
- Category: HCV Sexual Transmission
- Published on Friday, 05 November 2010 12:48
Less than 1% of HIV positive gay and bisexual men seen at a Danish hospital were found to have acute hepatitis C virus (HCV) infection, according to a study presented at the American Association for the Study of Liver Diseases "Liver Meeting" (AASLD 2010) this week in Boston. All those who started hepatitis C treatment within 6 months of becoming infected achieved rapid virological response, while 1 who started later experienced HCV relapse.
July 28 Is World Hepatitis Day
- Details
- Category: Hepatitis B
- Published on Wednesday, 26 January 2011 00:00
Thursday, July 28, is World Hepatitis Day, an opportunity to raise awareness about life-threatening viral hepatitis. Over years or decades hepatitis B and C can progress to severe liver disease including cirrhosis and liver cancer. Viral hepatitis is a leading indication for liver transplants worldwide.
Boceprevir Improves Response to Interferon-based Therapy and Allows Many Patients to Reduce Duration
- Details
- Category: HCV Treatment
- Published on Tuesday, 02 November 2010 13:48
Final results from 2 pivotal Phase 3 clinical trials presented at the American Association for the Study of Liver Diseases "Liver Meeting" (AASLD 2010) this week in Boston showed that adding Merck's experimental hepatitis C virus (HCV) NS3 protease inhibitor boceprevir to standard therapy increased the likelihood of sustained virological response for both previously untreated and treatment-experienced genotype 1 chronic hepatitis C patients.
More Articles...
- Can Chronic Hepatitis C Patients with Genotypes 2 or 3 Benefit from Shorter Interferon Treatment?
- HIV Coinfection Does Not Worsen Liver Transplant Outcomes in People with Hepatitis B or C
- Does CD4 Cell Count Influence Liver Fibrosis in HIV/HCV Coinfected People?
- FDA Suspends Trials of Experimental HCV Regimen IDX184 plus IDX320 Due to Liver Toxicity Concerns
- Acute Hepatitis C as a Sexually Transmitted Infection in HIV Positive Men
Web Design and Development by